Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:depression
|
| gptkbp:approves |
gptkb:2009
gptkb:FDA |
| gptkbp:chemical_formula |
C19 H24 N2 O
|
| gptkbp:contraindication |
hypersensitivity to iloperidone
|
| gptkbp:developed_by |
gptkb:Novartis
|
| gptkbp:dosage_form |
gptkb:tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Fanapt
|
| gptkbp:ingredients |
iloperidone
|
| gptkbp:interacts_with |
CYP2 D6 inhibitors
CYP3 A4 inhibitors |
| gptkbp:marketed_as |
gptkb:Fanapt
|
| gptkbp:route_of_administration |
oral
|
| gptkbp:side_effect |
dizziness
fatigue nausea dry mouth weight gain |
| gptkbp:strength |
10 mg
1 mg 12 mg 6 mg 8 mg 2 mg 16 mg 4 mg 20 mg |
| gptkbp:used_for |
schizophrenia
|